Investigation of structure-activity relationships of novel quinazoline
s has identified a 4-(4-iso-quinolylamino)-quinazoline and a 4-(trans-
2-phenylcyclopropylamino)-quinazoline as potent inhibitors of EGF-rece
ptor tyrosine kinase in vitro. Further modifications of the latter com
pound have identified a derivative which shows anti-tumour activity ag
ainst a tumour xenograft model when dosed orally once per day. (C) 199
7 Elsevier Science Ltd.